Kangmei Pharmaceutical Co Ltd

SHSE:600518

Chiny / Opieka zdrowotna / Farmaceutyki

Podsumowanie

Dywidendy

Historyczne dane finan. z 5 lat

Cena akcji

2,13 CNY


Key Metrics	Latest
Total Revenue	5,213 B
Adjusted EBITDA	545 M
EBITDA Margin	10,5%
Net Profit Margin	5,9%
Total Assets	14,194 B
Total Debt	215,9 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	12 Months	Sep-23	Sep-24

Revenue	11,445.55	5,412.01	4,152.52	4,180.15	4,874.02	5,213.45	3,534.12	3,873.56
% Growth		(0.53)	(0.23)	0.01	0.17			0.10

Adjusted EBITDA	(1,009.29)	(26,147.68)	(2,493.30)	(730.42)	490.98	545.02	25.12	79.17
% Margin	(0.09)	(4.83)	(0.60)	(0.17)	0.10	0.10	0.01	0.02

Adjusted EBIT	(1,704.42)	(26,792.50)	(3,046.50)	(1,040.34)	205.36	277.63	(207.32)	(135.05)
% Margin	(0.15)	(4.95)	(0.73)	(0.25)	0.04	0.05	(0.06)	(0.03)

Adjusted Net Income	(3,895.02)	(29,659.84)	(1,752.21)	(1,532.33)	159.80	309.63	(162.24)	(12.42)
% Margin	(0.34)	(5.48)	(0.42)	(0.37)	0.03	0.06	(0.05)	(0.00)

Adjusted Basic EPS	(0.79)	(2.15)	(0.13)	(0.11)	0.02	0.03	(0.01)	(0.00)

Obliczenia pomocnicze

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
CNY	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Sep-24	Sep-23	Sep-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	11,446	5,412	4,153	4,180	4,874	5,213	3,534	3,874
% Growth	NA	-52.7%	-23.3%	0.7%	16.6%			9.6%

Cost of Revenue	(10,498)	(29,046)	(4,061)	(3,749)	(4,159)	(4,548)	(2,936)	(3,325)
Gross Profit	948	(23,634)	92	431	715	665	598	548
% Revenue	8.3%	-436.7%	2.2%	10.3%	14.7%	12.8%	16.9%	14.2%

Research and Development	(110)	(11)	(9)	(25)	(46)	(40)	(38)	(32)
Selling and Marketing	(1,091)	(685)	(449)	(464)	(548)	(424)	(437)	(313)
General and Admin	(1,233)	(2,339)	(2,027)	(787)	(228)	(230)	(318)	(320)
Other Inc / (Exp)	(1,430)	(2,202)	11,376	(1,781)	198	253	14	69
Total Operating Exp	(3,863)	(5,237)	8,892	(3,057)	(624)	(441)	(779)	(597)

Operating Income	(2,915)	(28,871)	8,983	(2,626)	91	224	(181)	(48)
% Revenue	-25.5%	-533.5%	216.3%	-62.8%	1.9%	4.3%	-5.1%	-1.2%

Interest Expense	(1,476)	(2,162)	(828)	(38)	19	38	48	67
Pre-tax Income	(4,391)	(31,033)	8,155	(2,664)	110	262	(133)	19
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(264)	(63)	(235)	(30)	(7)	(4)	(14)	(11)
Net Income to Company	(4,655)	(31,096)	7,920	(2,694)	104	258	(147)	8
% Margin	-40.7%	-574.6%	190.7%	-64.4%	2.1%	5.0%	-4.1%	0.2%

Minority Interest in Earnings	(5)	11	(2)	6	(1)	(3)	(1)	(3)
Net Income to Stockholders	(4,661)	(31,085)	7,918	(2,688)	103	256	(148)	5

Preferred Dividends	225	0	0	0	0	0	0	0
Other Adj.	(450)	0	0	0	0	0	0	0

Net Income to Common	(4,886)	(31,085)	7,918	(2,688)	103	256	(148)	5
% Margin	-42.7%	-574.4%	190.7%	-64.3%	2.1%	4.9%	-4.2%	0.1%

As Reported
Basic EPS (Continuing Ops)	(0.99)	(2.25)	0.57	(0.19)	0.01	0.02	(0.01)	0.00
Diluted EPS (Continuing Ops)	(0.99)	(2.25)	0.57	(0.19)	0.01	0.02	(0.01)	0.00

WA Basic Shares Out.	4,937.03	13,815.48	13,891.05	14,148.21	10,252.12	10,660.62	13,455.37	13,863.87
WA Diluted Shares Out.	4,937.03	13,815.48	13,891.05	14,148.21	10,252.12	10,660.62	13,455.37	13,863.87

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(4,391)	(31,033)	8,155	(2,664)	110	262	(133)	19
Addback: Net Interest Expense	1,476	2,162	828	38	(19)	(38)	(48)	(67)
Addback: Other Non Operating Expenses, Total	184	138	1,041	16	38	(16)	(5)	(59)
Addback: Depreciation & Amortization	695	645	553	310	286	267	232	214
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	111	44	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	5	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	19	45	(64)	(1)	(20)	(27)	(20)	(28)
Addback: Asset Writedown	477	1,424	2,634	307	100	101	(1)	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	500	516	1,576	331	37	37	0	0
Addback: Other Unusual Items	(80)	(94)	(17,217)	932	(41)	(41)	0	0
Adjusted EBITDA	(1,009)	(26,148)	(2,493)	(730)	491	545	25	79
% Margin	-8.8%	-483.1%	-60.0%	-17.5%	10.1%	10.5%	0.7%	2.0%

Adjusted EBIT	(1,704)	(26,793)	(3,046)	(1,040)	205	278	(207)	(135)
% Margin	-14.9%	-495.1%	-73.4%	-24.9%	4.2%	5.3%	-5.9%	-3.5%

Adjusted Net Income Reconciliation
Net Income to Company	(4,655)	(31,096)	7,920	(2,694)	104	258	(147)	8
Addback: Unusual Items	1,027	1,941	(13,070)	1,570	76	69	(21)	(28)
Less: Tax Benefit of Unusual Items (26%)	(267)	(505)	3,398	(408)	(20)	(18)	6	7
Adjusted Net Income	(3,895)	(29,660)	(1,752)	(1,532)	160	310	(162)	(12)
% Margin	-34.0%	-548.0%	-42.2%	-36.7%	3.3%	5.9%	-4.6%	-0.3%

Wszelkie prawa zastrzeżone. Warunki używania

Błąd ładowania

Kangmei Pharmaceutical Co Ltd

SHSE:600518

Chiny / Opieka zdrowotna / Farmaceutyki

Historyczne dane finan. z 5 lat